This application is a competitive renewal focused on developing 6DBF7, a novel dibenzofuran (DBF)- based partial peptide mimetic of anginex, as an antiangiogenic and antitumor agent for use in the management of human cancer in the clinic. Antiangiogenic compounds have considerable potential as therapeutic agents, as has been recently demonstrated in the clinic with the anti-VEGF antibody Avastin. We recently discovered that the molecular target of 6DBF7, like parent anginex, is galectin-1, a novel receptor in the tumor angiogenesis field. Because galectin-1 mediates tumor angiogenesis by promoting endothelial cell adhesion and migration and is found to be highly expressed in human tumors, it is a prime target for therapeutic intervention. Therefore, optimization of 6DBF7 as an effective therapeutic agent and antagonist of galectin-1 forms the basis of this application. Here, we propose an integrated approach to drug discovery that involves the design, synthesis, and evaluation of new 6DBF7 analogs in the context of the following aims:
Aim 1 Determine the NMR structure of 6DBF7 in complex with galectin-1 and assess binding of new 6DBF7 analogs to galectin-1;
Aim 2 Enhance the antiangiogenic activity and galectin-1 binding of 6DBF7 using structure-based and focused library-based approaches;
Aim 3 Investigate in vivo exposure and efficacy of selected analogs of 6DBF7 identified from Aim 2. This application presents a comprehensive and integrated plan that will enable us to capitalize on the exciting discovery of the antiangiogenic and antitumor properties of 6DBF7 as an antagonist of galectin-1 Based on our extensive preliminary results, we are well-positioned to achieve the Aims of this study and advance the compound along the pre-clinical pathway toward clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA096090-08
Application #
7835794
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Lees, Robert G
Project Start
2002-04-01
Project End
2012-04-30
Budget Start
2010-05-07
Budget End
2011-04-30
Support Year
8
Fiscal Year
2010
Total Cost
$299,113
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Biochemistry
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Rauthu, Subhash R; Shiao, Tze Chieh; André, Sabine et al. (2015) Defining the potential of aglycone modifications for affinity/selectivity enhancement against medically relevant lectins: synthesis, activity screening, and HSQC-based NMR analysis. Chembiochem 16:126-39
Ippel, Hans; Miller, Michelle C; Berbís, Manuel Alvaro et al. (2015) (1)H, (13)C, and (15)N backbone and side-chain chemical shift assignments for the 36 proline-containing, full length 29 kDa human chimera-type galectin-3. Biomol NMR Assign 9:59-63
Dings, Ruud P M; Kumar, Nigam; Miller, Michelle C et al. (2013) Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1. J Pharmacol Exp Ther 344:589-99
Ermakova, Elena; Miller, Michelle C; Nesmelova, Irina V et al. (2013) Lactose binding to human galectin-7 (p53-induced gene 1) induces long-range effects through the protein resulting in increased dimer stability and evidence for positive cooperativity. Glycobiology 23:508-23
Dings, Ruud P M; Levine, Joseph I; Brown, Susan G et al. (2013) Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. Invest New Drugs 31:1142-50
Kumar, Nigam; Ippel, Hans; Weber, Christian et al. (2013) Protein lysine-N? alkylation and O-phosphorylation mediated by DTT-generated reactive oxygen species. Protein Sci 22:327-46
Miller, Michelle C; Klyosov, Anatole A; Mayo, Kevin H (2012) Structural features for ?-galactomannan binding to galectin-1. Glycobiology 22:543-51
Nesmelova, Irina V; Berbís, Manuel Álvaro; Miller, Michelle C et al. (2012) 1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 31 kDa human galectin-7 (p53-induced gene 1) homodimer, a pro-apoptotic lectin. Biomol NMR Assign 6:127-9
Dings, Ruud P M; Miller, Michelle C; Nesmelova, Irina et al. (2012) Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem 55:5121-9
Dings, Ruud P M; Vang, Kieng B; Castermans, Karolien et al. (2011) Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin Cancer Res 17:3134-45

Showing the most recent 10 out of 33 publications